NCT06264609
Precision Medicine Approach for Osteoporosis - Follow Up Study
Enrolling by Invitation
PHASE4Ages 45+InterventionalTreatmentPaul F NetzelInvestigator-initiated
~40 participants
Updated 2026-04-01 on ClinicalTrials.gov
What's tested:AlendronateTeriparatide
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percent change in bone loss
Measured over 12 months
Conditions
Where it's being run
1 sites across 1 statesKentucky1
Study leadership
- Paul Netzel, DNP · PRINCIPAL_INVESTIGATOR · University of Kentucky
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Percent change in bone loss12 months
The primary endpoint for the follow up study will be bone loss as determined by the percent change in DXA absolute values of the lumbar spine, femoral neck, total hip and radius measured at baseline, at the end of the one-year trial; and at end of the one year follow up study. DXA is chosen because of its wide availability, low radioactivity exposure, and clinical use.